S-NGR-TNF

S-NGR-TNF is an engineered recombinant fusion protein consisting of tumor necrosis factor-alpha (TNF) fused to a Cys-Asn-Gly-Arg-Cys-Gly (NGR) peptide ligand. It is designed to target aminopeptidase N (CD13), which is highly expressed on the endothelial cells of angiogenic tumor blood vessels. S-NGR-TNF is a second-generation derivative of NGR-TNF, modified with an N-terminal serine residue to improve molecular stability and reduce structural heterogeneity. The drug functions by altering the blood-brain tumor barrier (BBTB) and increasing the intratumoral delivery of co-administered chemotherapeutic agents. Additionally, it modulates the tumor microenvironment by reducing the infiltration of immunosuppressive cells such as regulatory T cells and M2 macrophages. Preclinical studies have demonstrated synergistic activity with temozolomide in glioblastoma and efficacy in lymphoma and sarcoma models.

Other names

serine-NGR-TNFengineered tumor necrosis factor